Strongbridge Biopharma plc (NASDAQ:SBBP) has earned a consensus rating of “Buy” from the six ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $13.50.

Several analysts have issued reports on SBBP shares. Zacks Investment Research lowered Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research note on Wednesday, November 22nd. ValuEngine lowered Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Cantor Fitzgerald started coverage on Strongbridge Biopharma in a research note on Tuesday. They issued a “buy” rating and a $14.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Strongbridge Biopharma in a research note on Wednesday, November 15th. Finally, Oppenheimer started coverage on Strongbridge Biopharma in a research note on Thursday, August 10th. They issued an “outperform” rating and a $12.00 target price for the company.

Shares of Strongbridge Biopharma (NASDAQ:SBBP) traded up $0.10 on Tuesday, reaching $6.40. The company’s stock had a trading volume of 98,800 shares, compared to its average volume of 108,589. The company has a quick ratio of 4.61, a current ratio of 4.70 and a debt-to-equity ratio of -1.89. Strongbridge Biopharma has a 1-year low of $2.00 and a 1-year high of $8.85.

Several large investors have recently added to or reduced their stakes in the company. State of Wisconsin Investment Board purchased a new stake in shares of Strongbridge Biopharma during the second quarter valued at approximately $114,000. Rhumbline Advisers purchased a new stake in shares of Strongbridge Biopharma during the second quarter valued at approximately $154,000. California State Teachers Retirement System purchased a new stake in shares of Strongbridge Biopharma during the second quarter valued at approximately $277,000. Teachers Advisors LLC purchased a new stake in shares of Strongbridge Biopharma during the second quarter valued at approximately $297,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Strongbridge Biopharma during the second quarter valued at approximately $331,000. 57.53% of the stock is owned by hedge funds and other institutional investors.

WARNING: This piece of content was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/08/analysts-set-strongbridge-biopharma-plc-sbbp-price-target-at-13-50.html.

About Strongbridge Biopharma

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Receive News & Stock Ratings for Strongbridge Biopharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma plc and related stocks with our FREE daily email newsletter.